Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PharmAsia News' Top Industry Trends Of 2009

This article was originally published in PharmAsia News

Executive Summary

As PharmAsia News wraps up its second year of publishing, we look back to some of the top trends and stories of 2009, as well as developing stories to keep an eye on in 2010

You may also be interested in...



China Boosts Health System Reforms With Expanded National Drug Reimbursement List

BEIJING - In the government's latest move to expand coverage under sweeping health system reforms that are in the works China-wide, the Ministry of Human Resources and Social Security has added hundreds of new medicines to the latest edition of the national drug reimbursement catalog

Investment Outlook For China And India Too Hot? VCs Anticipate Market Corrections - PharmAsia Summit

SAN FRANCISCO - Investors have not felt the pinch of the financial crisis in China and India as much as they have in the West, investors told PharmAsia Summit attendees in San Francisco Oct. 28

Partnering Better Than Solo Play For Biosimilars, Says Dr. Reddy's CEO; Limited Growth In Generics Will Lead To Moves For Innovative Drugs

MUMBAI - With six biosimilar compounds in the works and two launched in the Indian market, India's second largest generic drug maker - Dr. Reddy's Labs - is negotiating with several multinational companies to broaden its presence in Western markets

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC073156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel